Here, we provide three different methods for measuring the physical dimension of CRF. Motor fatigue tests using handheld dynamometers are simple and easily adaptable for clinical use. Since many variations of the test exist in the literature, our goal was to provide standardized methods to administer these tests and decrease the need for extensive in-person trainings for clinicians.
Although the fatigue tests outlined in this study demonstrate good test-retest reliability7,20, adherence to this protocol will ensure data reproducibility. A critical and often overlooked step during test preparation is to allow the handgrip device to calibrate on a flat surface. This step will establish an actual baseline reading. Even though maximal strength is not an accurate indicator for the physical aspect of CRF13, obtaining the true MVIC value will greatly enhance data interpretation. It is used to determine if motor weakness is present via normative data comparisons24. Accurate MVIC values also ensure that the static fatigue test is an actual maximal performance test, facilitating normative comparisons for fatigue indices. Motor fatigue tests are particularly helpful in a clinical setting where the static fatigue test may be used as a screening tool in addition to making longitudinal comparisons. We recommend that Fmax be inspected and be within 10% of MVIC to ensure the maximal static fatigue test does not become a de facto submaximal test. Consistent with previous studies, we found that verbal encouragement during handgrip fatigue tests is necessary for achieving reproducible data and a good Fmax (± 10% of MVIC)25,26. Maintaining maximal contraction, particularly during the static fatigue test, requires concentration and motivation. In the absence of verbal encouragement, subjects at times fail to achieve the true maximal contraction during the first 5 s or during the entire test, which introduces variability in static fatigue index (SFI) calculations. Related to this point, a standard script should be used when providing instructions before the test and during verbal encouragement, consistent with previous studies25,26.
SFI version 1 (Figure 2A) represents the difference between curves of the actual force-versus-time and the hypothetical force-versus-time in the absence of fatigue. Multiple variations of the calculations have been developed in previous studies20. Since subjects typically reach maximal force within the first 5 s, the following modifications can be used to calculate the actual area under the curve (AUCexpt): (1) AUC from 5 to 30 s of the test, (2) the entire duration of the test from 0–30 s, and (3) the total AUC from when Fmax is achieved (Tmax) to 30 s after that12,20. The time interval used to calculate AUCexpt value is then used to determine the time interval for calculating the hypothetical AUC (AUChypothetical) in the absence of fatigue, which is typically calculated as Fmax multiplied by the time duration used to derive AUCexpt. In our experience, CRF correlates significantly with the SFI calculated using the method outlined in Figure 2A13. Given the variability of the amount of time necessary to reach Fmax particularly in older patients with cancer, SFI version 1 described in the methods section provides the most sensitive measure to capture the physical dimension of CRF with no loss of data showing early fatiguing, as would occur with looking only at AUC from 5–30 s13.
SFI calculation version 2 (Figure 2B) represents the decline in maximal force generated from the beginning of the test to the end of the test. The calculation method is much simpler than SFI version 1 and provides a quick way to estimate the level of fatigue. However, static fatigue index calculation version 2 exhibited low test-retest reliability with an interclass correlation coefficient (ICC) of 0.46–0.77, while static fatigue index version 1 demonstrated higher test-retest reliability of 0.71–0.96 in Multiple Sclerosis (MS) patients21. This is consistent with our finding that only static fatigue test and SFI calculation version 1 correlated significantly with self-reported fatigue in patients with prostate cancer13. Interestingly, SFI version 1 exhibited lower test-retest reliability (ICC of 0.18-0.52) in healthy controls compared to their MS counterparts21. Therefore, we recommend using SFI calculation version 1 for measuring physical fatigue in patients with cancer. SFI version 2 may be used for providing a quick estimate of fatigue levels during the test.
The submaximal fatigue test consists of either sustained (static) or repetitive (dynamic) contractions at a target value of 30–75% of MVIC. While this test is not typically used to calculate motor fatigability, we included this method in the current protocol because it is often used to induce fatigue during concurrent assessments such as drug treatment effects, blood biomarker analysis, electromyography, and functional magnetic resonance imaging (fMRI)27,28,29. Submaximal fatigue tests cause less discomfort in research subjects30. These tests also better approximate typical daily tasks such as grasping and carrying groceries. In addition, the submaximal fatigue test may be more sensitive to additional treatment-induced effects31. Performance on the submaximal fatigue test can be gauged as total work performed (Figure 2C), which has demonstrated good test-retest reproducibility7. Alternatively, time to task failure, or endurance, has also been used to quantify submaximal fatigue test performance22.
Dynamic fatigue tests consist of intermittent repeated maximal contractions, usually at a fixed rhythm guided with a metronome7. The dynamic fatigue index (DFI) is calculated as the drop in maximal force from the beginning to the end of the test (Figure 2D). The DFI calculation described in the methods considers the maximal force (Fmax) generated during the first and last 3 contractions. This method can be modified to take into account the Fmax in the first 5 s (0–5s) and the last 5 s (25–30 s)20. Similar to the submaximal fatigue test, the dynamic fatigue test causes less discomfort and has good test-retest reliablity7. However, the dynamic fatigue test did not demonstrate sufficient discriminative power in studies comparing fatigued subjects (e.g., post-polio, multiple sclerosis) and healthy controls20.
Motor fatigue measured using the handgrip device may originate from either decreased drive from the descending efferent motor neurons, or impaired contractile mechanisms within muscle fibers5. Interestingly, submaximal contractions may be more influenced by the motor cortex, whereas maximal fatigue tests may have a greater muscular component32. This may be related to the prolonged ischemia induced by high intramuscular pressure (>50% MVIC) and decreased blood flow into muscle tissues29,33. Contractile forces measured using handheld dynamometers involve the adductor pollicis containing predominant Type 1 fibers, as well as forearm flexor digitorium muscles comprised of both Type I and II fibers34. Due to the highly oxidative nature of Type I fibers, maximal static fatigue tests are more prone to muscle ischemia and glycolysis-induced fatigue35. Since submaximal fatigue tests and dynamic/intermittent tests allow for muscle fiber recovery, they may be more useful for assessing physical fatigue with a central origin33. Future studies that aim to isolate contributions of motor neurons versus muscular components may also include transcranial magnetic stimulation of the motor cortex used in conjunction with electromyogram recordings36.
A limitation of the current protocol is that the lack of a well-established normative value for the cancer population using these physical fatigue tests. Previous studies have measured physical fatigue using the handgrip device in populations prone to developing physical fatigue such as polio and aging20,23. Such normative values have yet to be established in cancer fatigue research using standardized methods. In addition, variables such as hand size, the type of handheld dynamometer, the presence of non-slip gloves or rings, hand dominance, gender, age, and baseline fitness can affect handgrip tests. The inevitable heterogeneity of clinical populations may limit the generalizability of study results from using the handgrip test. Therefore, strategies to control for these potential confounding variables should be considered, such as analysis of covariance or MVIC data normalization to body weight. Further, the handgrip test only captures fatiguability of upper limb muscle tissues, which may not correlate with lower limb fatigability26. Careful data interpretation and avoiding over-generalization are, therefore, warranted when using the handgrip test to measure the physical dimension of CRF. It may be helpful to include additional performance fatigability tests that involve lower extremities, such as the 6 min or 10 m walk test, in conjunction with handgrip fatigability tests37. Finally, the methods described in the current study represent motor fatigue measured at a single time point. Previous studies have shown that fatigability, which reflects the change in fatigue during an activity, may be more useful clinically as this concept captures the functional status of the patient38. Future studies will explore the association between perceived fatigability (change in self-reported fatigue scores) and performance fatigability (change in handgrip fatigue indices) before and after physical/cognitive tests37,38,39.
In conclusion, the methods outlined in this protocol provide objective and quantitative measures of a debilitating symptom and are easily applicable in the clinical setting. In our experience, the static fatigue test combined with SFI calculation version 1 is the most sensitive method for capturing the physical aspect of fatigue in cancer as well as other disease conditions12,13. In addition to the static maximal fatigue test, we provided two additional handgrip tests which are less fatiguing and may be better tolerated in severely impaired patient populations. Variables such as age, gender, disease, and baseline fitness level can all affect physical fatigue measurements using the handgrip device. The specific method used should be tailored to each disease population.